Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
BioPharma DiveBen FidlerNovember 20, 2026
Wall Street analysts rushed to Celldex s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva s research chief accepted a new job.
